丽珠医药集团股份有限公司（港股代码01513，深圳证券交易所主板代码000513）于2026年9月1日发布2026年8月股份变动月报表，报告期为2026年8月1日至2026年8月31日。
根据公告，报告期内公司注册股本维持人民币887,907,171元不变；H股数量299,807,117股，A股数量588,100,054股，均与上月持平。公司当月无新增发行股票、购回、注销或库藏股变动，也无股份期权及其他股权激励计划的变动。
截至2026年8月末，公司已满足相关公众持股量要求。公告由公司秘书刘宁签署。公司称，所有相关发行事项均严格遵守香港联合交易所有限公司《上市规则》及其他适用法律法规的要求。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.